The activated antitumor immunity, elevated PD-L1, PD-L2 and CTLA-4 expression, and heightened tumor immunogenicity likely explain why the low-risk group benefits from ICI therapy compared to their high-risk counterparts. This evidence concerns the gene PDCD1LG2 and neoplasm.